BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS

本合同的目的是促进进入 生物反应调节剂（BRM）进入临床试验。 这将 通过检查BRM在以下方面的潜在功效来实现 合适的逆转录病毒感染的动物模型。 着力 用于单独或与其他药物联合评估BRM 在适当的动物/逆转录病毒模型中， 作为治疗艾滋病的潜在用途。 BRM是代理或 用来改变宿主对感染的生物反应的方法 从而产生治疗效果。 BRM可以在以下方面发挥作用： 几种方式。 有些通过以下方式增加宿主的抗病毒反应： 直接或间接地增大或恢复效应臂。 其他的则可能起到增加细胞生长和分化的作用。 淋巴细胞或巨噬细胞，从而增加了细胞的能力， 宿主耐受细胞毒性药物的损害， 艾滋病的治疗。 细胞因子、淋巴因子、单核因子， 生长因子、肿瘤坏死因子及其诱导物 蛋白质是迄今已知的一些BRM的实例。 的 国家癌症中心癌症治疗处（DCT） 该研究所一直在开发这些药物， 肿瘤的 直到最近，人们还没有做多少工作来开发 单独使用BRM或与其他药物联合使用 病毒感染的治疗。 艾滋病的治疗方法 其需要用抗病毒剂（例如， 核苷类似物）可能需要与 免疫反应的调节因子。 BRM可用于 减少药物的毒性通过增加 淋巴细胞或援助的免疫反应，对这种病毒 感染 目前，对这一领域的研究需要 增加 本次征集的目的是开发使用 用于艾滋病治疗。 这将通过 单独或与其他药物联合使用BRM的评价 逆转录病毒是一种模仿艾滋病的动物模型。

The objective of this contract is to facilitate the entry of biological response modifiers (BRMs) into clinical trials. This will be accomplished by examining the potential efficacy of BRMs in an appropriate retrovirus infected animal model. Efforts will be made to evaluate BRMs alone or in combination with other drugs in an appropriate animal/retrovirus model to determine their potential usefulness as a therapy for AIDS. BRMs are agents or methods used to alter the host's biological response to infection with a resultant therapeutic effect. BRMs may function in several ways. Some increase the host's antiviral responses by augmenting or restoring the effector arms directly or indirectly. Others may function to increase the growth and differentiation of lymphocytes or macrophages thus increasing the ability of the host to tolerate damage by cytotoxic drugs that may be used in the treatment of AIDS. Cytokines, lymphokines, monokines, growth factors, tumor necrosis factors and inducers of these proteins are examples of some of the BRMs known to date. The Division of Cancer Treatment (DCT) of the National Cancer Institute has ben developing these agents in the treatment of tumors. Until recently little work has been done to develop the use of BRMs alone or in combination with other drugs for the treatment of viral infections. It may be that therapies for AIDS which require long term treatment with an antiviral agent (e.g. nucleoside analogue) may require combination therapy with a modualtor of the immune response. BRMs could be used to decrease the toxicity of the drug by increasing the number of lymphocytes or aid in the immune response against this viral infection. At present, research into this area needs to be increased. It is the purpose of this solicitation to develop the use of BRMs for AIDS therapy. This will be accomplished by evaluation BRMs alone or in combination with other drugs in an retrovirusanimal model which mimics the disease AIDS.